WO2012099441A3 - Immune response inhibiting composition containing stem cells expressing tryptophan metabolizing enzyme genes - Google Patents

Immune response inhibiting composition containing stem cells expressing tryptophan metabolizing enzyme genes Download PDF

Info

Publication number
WO2012099441A3
WO2012099441A3 PCT/KR2012/000556 KR2012000556W WO2012099441A3 WO 2012099441 A3 WO2012099441 A3 WO 2012099441A3 KR 2012000556 W KR2012000556 W KR 2012000556W WO 2012099441 A3 WO2012099441 A3 WO 2012099441A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
mesenchymal stem
expressed
inhibiting composition
cells expressing
Prior art date
Application number
PCT/KR2012/000556
Other languages
French (fr)
Korean (ko)
Other versions
WO2012099441A2 (en
Inventor
서수길
이영숙
박세광
최일환
Original Assignee
인제대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인제대학교산학협력단 filed Critical 인제대학교산학협력단
Priority claimed from KR1020120006704A external-priority patent/KR20120085209A/en
Publication of WO2012099441A2 publication Critical patent/WO2012099441A2/en
Publication of WO2012099441A3 publication Critical patent/WO2012099441A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

The present invention relates to mesenchymal stem cells expressing tryptophan metabolizing enzyme genes and to an immune inhibiting composition comprising the same. More particularly, kynurenine-3-hydroxylase and kynureninase which are tryptophan metabolizing enzymes which are not naturally expressed from mesenchymal stem cells are expressed in mesenchymal stem cells, to thereby effectively inhibit alloantigen-reactive T cells of mesenchymal stem cells and thus increase immunosuppressive effects. The mesenchymal stem cells in which kynurenine-3-hydroxylase and kynureninase are expressed may provide more enhanced immunosuppressive effects than mesenchymal stem cells in which those enzymes are not expressed, and therefore, may effectively prevent and treat diseases caused by T-cell overactivation, including graft-versus-host diseases.
PCT/KR2012/000556 2011-01-21 2012-01-20 Immune response inhibiting composition containing stem cells expressing tryptophan metabolizing enzyme genes WO2012099441A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2011-0006306 2011-01-21
KR20110006306 2011-01-21
KR10-2012-0006704 2012-01-20
KR1020120006704A KR20120085209A (en) 2011-01-21 2012-01-20 Composition for inhibiting immune response comprising stem cell expressing tryptophan metabolic enzyme gene

Publications (2)

Publication Number Publication Date
WO2012099441A2 WO2012099441A2 (en) 2012-07-26
WO2012099441A3 true WO2012099441A3 (en) 2012-10-18

Family

ID=46516272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/000556 WO2012099441A2 (en) 2011-01-21 2012-01-20 Immune response inhibiting composition containing stem cells expressing tryptophan metabolizing enzyme genes

Country Status (1)

Country Link
WO (1) WO2012099441A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3173052A1 (en) * 2013-08-30 2015-03-05 Board Of Regents, The University Of Texas System Administration of kynurenine depleting enzymes for tumor therapy
US9975959B2 (en) 2014-08-29 2018-05-22 Board Of Regents, The University Of Texas System Administration of kynurenine depleting enzymes for tumor therapy
KR101739659B1 (en) * 2015-01-23 2017-05-24 가톨릭대학교 산학협력단 Mesenchymal stem cells overexpressing Grim19 having treating immune disease and use thereof
WO2016117960A1 (en) * 2015-01-23 2016-07-28 가톨릭대학교 산학협력단 Mesenchymal stem cells over-expressed by grim19 efficacious in treating immune disease, and use thereof
US11542486B2 (en) 2016-03-02 2023-01-03 Board Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
SG11202009559RA (en) 2018-04-16 2020-10-29 Univ Texas Human kynureninase enzymes and uses thereof
WO2020056410A1 (en) * 2018-09-14 2020-03-19 The Children's Hospital Of Philadelphia Compositions and methods for modulating immunosuppression

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C. A. OPITZ ET AL.: "Tryptophan degradation in autoimmune diseases", CELL. MOL. LIFE SCI., vol. 64, no. 19/20, 2007, pages 2542 - 2563 *
CHRISTIANE A. OPITZ ET AL.: "Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-l via interferon-0 and protein kinase R", STEM CELLS, vol. 27, no. 4, 2009, pages 909 - 919 *
MARIOLA MATYSIAK ET AL.: "Stem cells ameliorate EAE via an indoleamine 2,3-dioxygenase (IDO) mechanism", JOURNAL OFNEUROIMMUNOLOGY, vol. 193, no. 1/2, 2008, pages 12 - 23 *
SOUFIANE GHANNAM ET AL.: "Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications", STEM CELL RESEARCH & THERAPY, vol. 1, no. 1, 2, 2010, ISSN: 1757-6512, Retrieved from the Internet <URL:http://stemcellres.com/content/1/1/2> *

Also Published As

Publication number Publication date
WO2012099441A2 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
WO2012099441A3 (en) Immune response inhibiting composition containing stem cells expressing tryptophan metabolizing enzyme genes
MX2010004674A (en) Alpha-amylase variants with altered properties.
PH12015501470A1 (en) Compositions and methods for the control of nematodes and soil borne diseases
WO2012058693A3 (en) Compositions and methods for inhibition of pcsk9 genes
IN2014CN02100A (en)
WO2010141801A3 (en) Reprogramming t cells and hematophietic cells
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
PH12014502445B1 (en) Targeted modification of malate dehydrogenase
WO2012058494A3 (en) Isoprene synthase variants for improved production of isoprene
WO2008085221A3 (en) Therapeutic use of cd31 expressing cells
NZ700760A (en) 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
WO2012019122A3 (en) Simplified basic media for human pluripotent cell culture
WO2012037155A3 (en) Tyrosine kinase inhibitors
EA201291107A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
IN2014MN00989A (en)
WO2011083150A3 (en) Obesity small molecules
MX355504B (en) Acyl-acp wax ester synthases.
WO2012024573A3 (en) Compositions comrpising perivascular stem cells and nell-1 protein
MX2012004559A (en) Methods and systems for pharmacogenomic treatment of cardiovascular conditions.
EA201390592A1 (en) ALLEYS 1-D-DEOXYXILULOUSO-5-PHOSPHATE SYNTHESIS RESPONSIBLE FOR STRENGTHENED TERPENES Biosynthesis
MX349801B (en) Nucleic acid enzyme substrates.
WO2012012676A3 (en) Use of mir-29 for cell protection
WO2010140862A3 (en) MULTI-CISTRONIC shRNA EXPRESSION CASSETTE FOR SUPPRESSING SINGLE OR MULTIPLE TARGET GENES
MX2011010763A (en) Plant promoter operable in endosperm and uses thereof.
MX2016008850A (en) Method of increasing biomass and lipid content in a micro-organism and a genetically modified micro-organism exhibiting enhanced autophagy.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12736884

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12736884

Country of ref document: EP

Kind code of ref document: A2